RU2017139718A - AGENT, INDUCING CELLULAR DESTRUCTION, FOR CELLS, which is equipped with a drawing-up of text-taking graphics (APIs), EPS AGENT, GROWTH FOR THOSE CELLS, and PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES, IT-ALUMNI; - Google Patents

AGENT, INDUCING CELLULAR DESTRUCTION, FOR CELLS, which is equipped with a drawing-up of text-taking graphics (APIs), EPS AGENT, GROWTH FOR THOSE CELLS, and PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES, IT-ALUMNI; Download PDF

Info

Publication number
RU2017139718A
RU2017139718A RU2017139718A RU2017139718A RU2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A RU 2017139718 A RU2017139718 A RU 2017139718A
Authority
RU
Russia
Prior art keywords
cell
agent
mutation
cancer
pharmaceutical composition
Prior art date
Application number
RU2017139718A
Other languages
Russian (ru)
Other versions
RU2760835C2 (en
RU2017139718A3 (en
Inventor
Йосиро НИИТСУ
Хироки НИСИТА
Original Assignee
Нитто Денко Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2016078710A external-priority patent/JP6864990B2/en
Application filed by Нитто Денко Корпорейшн filed Critical Нитто Денко Корпорейшн
Publication of RU2017139718A publication Critical patent/RU2017139718A/en
Publication of RU2017139718A3 publication Critical patent/RU2017139718A3/ru
Application granted granted Critical
Publication of RU2760835C2 publication Critical patent/RU2760835C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

1. Агент, индуцирующий клеточную гибель, для клетки, имеющей мутацию в гене BRAF, включающий лекарственное средство, подавляющее GST-π, в качестве активного компонента.1. An agent that induces cell death for a cell that has a mutation in the BRAF gene, including a drug that suppresses GST-π, as an active component. 2. Агент, подавляющий клеточный рост для клетки, имеющей мутацию в гене BRAF, включающий лекарственное средство, подавляющее GST-π, в качестве активного компонента.2. An agent that inhibits cell growth for a cell that has a mutation in the BRAF gene, including a drug that suppresses GST-π, as an active component. 3. Агент по п. 1 или 2, где мутация представляет собой мутацию V600E.3. The agent according to claim 1 or 2, where the mutation is the V600E mutation. 4. Агент по п. 1 или 2, где клетка, имеющая мутацию в гене BRAF, представляет собой клетку, устойчивую к ингибитору BRAF.4. The agent according to claim 1 or 2, where the cell having a mutation in the BRAF gene is a cell resistant to the BRAF inhibitor. 5. Агент по п. 1 или 2, где лекарственное средство представляет собой вещество, выбранное из группы, состоящей из молекул РНК-интерференции, рибозимов, антисмысловых нуклеиновых кислот, ДНК/РНК-химерных полинуклеотидов и векторов, экспрессирующих по меньшей мере одно из них.5. The agent according to claim 1 or 2, where the drug is a substance selected from the group consisting of RNA interference molecules, ribozymes, antisense nucleic acids, DNA / RNA chimeric polynucleotides and vectors expressing at least one of them . 6. Агент по п. 1 или 2, где клетка, имеющая мутацию в гене BRAF, представляет собой раковую клетку, высоко экспрессирующую GST-π.6. The agent according to claim 1 or 2, where the cell having a mutation in the BRAF gene is a cancer cell highly expressing GST-π. 7. Фармацевтическая композиция для терапии заболевания, вызванного дефектом роста клетки, имеющей мутацию в гене BRAF, содержащая агент по любому из пп. 1-6.7. Pharmaceutical composition for the treatment of a disease caused by a growth defect of a cell having a mutation in the BRAF gene, containing the agent according to any one of claims. 1-6. 8. Фармацевтическая композиция по п. 7, где заболевание представляет собой рак.8. The pharmaceutical composition of claim 7, wherein the disease is cancer. 9. Фармацевтическая композиция по п. 8, где рак представляет собой рак, высоко экспрессирующий GST-π.9. The pharmaceutical composition of claim 8, wherein the cancer is a cancer that highly expresses GST-π. 10. Фармацевтическая композиция по п. 8, где раком является колоректальный рак или меланома.10. The pharmaceutical composition of claim 8, wherein the cancer is colorectal cancer or melanoma. 11. Способ скрининга агента, индуцирующего клеточную гибель, и/или агента, подавляющего клеточный рост для клетки, имеющей мутацию в гене BRAF, включающий выбор лекарственного средства, подавляющего GST-π.11. A method for screening an agent that induces cell death and / or an agent that inhibits cell growth for a cell that has a mutation in the BRAF gene, including the choice of a drug that suppresses GST-π. 12. Способ скрининга по п. 11, включающий12. The screening method according to claim 11, comprising этап контактирования тестируемого вещества с раковой клеткой,the stage of contacting the test substance with a cancer cell, этап измерения уровня экспрессии GST-π в клетке и этап выбора тестируемого вещества в качестве лекарственного средства, подавляющего GST-π, когда уровень экспрессии снижен по сравнению со случаем, измеренным в отсутствие тестируемого вещества.a step of measuring the expression level of GST-π in the cell and a step of selecting a test substance as a drug that suppresses GST-π when the expression level is reduced compared with the case measured in the absence of the test substance.
RU2017139718A 2015-04-16 2016-04-15 Agent inducing cell death for cells having braf gene mutations, agent suppressing growth of such cells, and pharmaceutical composition for the therapy of diseases caused by growth defect of such cells RU2760835C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015084286 2015-04-16
JP2015-084286 2015-04-16
JP2016-078710 2016-04-11
JP2016078710A JP6864990B2 (en) 2015-04-16 2016-04-11 A cell death inducer for cells having a BRAF gene mutation, a growth inhibitor of the cells, and a pharmaceutical composition for treating a disease caused by abnormal growth of the cells.
PCT/JP2016/062090 WO2016167340A1 (en) 2015-04-16 2016-04-15 Cell death inducing agent for cells having braf gene mutation, agent for inhibiting proliferation of said cells and pharmaceutical composition for treating patient suffering from effects of abnormal proliferation of said cells

Publications (3)

Publication Number Publication Date
RU2017139718A true RU2017139718A (en) 2019-05-16
RU2017139718A3 RU2017139718A3 (en) 2019-10-02
RU2760835C2 RU2760835C2 (en) 2021-11-30

Family

ID=57127072

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017139718A RU2760835C2 (en) 2015-04-16 2016-04-15 Agent inducing cell death for cells having braf gene mutations, agent suppressing growth of such cells, and pharmaceutical composition for the therapy of diseases caused by growth defect of such cells

Country Status (4)

Country Link
CN (1) CN116271056A (en)
PT (1) PT3284481T (en)
RU (1) RU2760835C2 (en)
WO (1) WO2016167340A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4245758A3 (en) 2017-10-26 2023-12-20 Xynomic Pharmaceuticals, Inc. Crystalline salts of a b-raf kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101786905B1 (en) * 2011-06-21 2017-10-19 닛토덴코 가부시키가이샤 Apoptosis-inducing agent
JP6340162B2 (en) * 2012-12-20 2018-06-06 日東電工株式会社 Apoptosis inducer
GB201312155D0 (en) * 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention

Also Published As

Publication number Publication date
PT3284481T (en) 2024-06-04
RU2760835C2 (en) 2021-11-30
CN116271056A (en) 2023-06-23
WO2016167340A1 (en) 2016-10-20
RU2017139718A3 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
Di Micco et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Amano et al. Telomere dysfunction induces sirtuin repression that drives telomere-dependent disease
Yip et al. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments
Hudgins et al. Age-and tissue-specific expression of senescence biomarkers in mice
Masui et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc
Mason et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent
Du et al. Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
Corsten et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease
Shibata et al. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels
Chamorro-Jorganes et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1
JP2011168588A5 (en)
EA201790420A1 (en) MEANS PRESENTING A MODIFIED TWO-STEAM RNA
Merrill et al. Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats
Porritt et al. Photothrombosis-induced infarction of the mouse cerebral cortex is not affected by the Nrf2-activator sulforaphane
Sharlo et al. Plantar mechanical stimulation prevents calcineurin-NFATc1 inactivation and slow-to-fast fiber type shift in rat soleus muscle under hindlimb unloading
JP2012050449A5 (en)
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
JP2011037847A5 (en)
RU2014101547A (en) Apoptosis-inducing agent
Zhou et al. Proteasome-independent protein knockdown by small-molecule inhibitor for the undruggable lung adenocarcinoma
US20090143451A1 (en) Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
Budini et al. Targeting TDP-43 in neurodegenerative diseases
WO2015048793A3 (en) Nucleic acid biomarker and use thereof
AR101440A1 (en) MULTIPLE ARNi DIRECTED FOR CANCER TREATMENT